Aptargroup, INC 10-Q quarterly reports

AptarGroup reported Q1 2026 net sales of $982.9 million, reflecting 11% growth driven by acquisitions and currency effects, despite flat core sales.

AptarGroup, Inc. reported a significant increase in net income and EPS for Q3 2025, driven by a one-time gain from an equity investment remeasurement and a lower effective tax rate, alongside modest core sales growth.

AptarGroup, Inc. announced a significant increase in net income and earnings per share for the second quarter and first half of 2025, fueled by robust performance in its Pharma and Closures segments and effective cost management.

AptarGroup's Q1 2025 net sales decreased by 3% year-over-year, primarily due to unfavorable foreign currency exchange rates, though the Pharma segment showed strong growth.

AptarGroup's Q3 2024 results show a 2% increase in net sales, primarily driven by strong performance in the Pharma segment, while also announcing a new $500 million share repurchase program.

AptarGroup's second quarter results show a 2% increase in net sales and improved profitability, driven by strong performance in the Pharma segment.

AptarGroup's first quarter of 2024 saw a 6% increase in net sales, driven by a strong performance in the Pharma segment and improved operational efficiencies.